Top

News & Events

Client News

Client News

Congenica completes Series B financing round with investments from China-based BGI, Healthlink and Future Planet

Cambridge, UK – Congenica, a world leader in clinical genomics software for inherited diseases, today announced completion of its recently announced Series B funding round with additional investments from new strategically important investors BGI Genomics (BGI), a recognized global leader in genomics, Healthlink Capital (Healthlink), another well-established China-based life-science investor and Future Planet Capital, a global innovation fund.

Read more »

Adherium presents its Smartinhaler™ data at Respiratory Drug Delivery Europe 2017

Melbourne, Australia - Adherium Limited (ASX: ADR, ‘Adherium’), a global leader in digital health technologies addressing sub-optimal medication use in chronic disease, will today present data on its proprietary Smartinhaler™ platform at the Respiratory Drug Delivery Europe conference 2017 (RDD Europe).

Read more »

Abzena to pursue $12 million investment program to upgrade and expand its San Diego biomanufacturing operations

San Diego CA, USA – Abzena intends to invest $12 million at its San Diego facilities in order to upgrade and expand its biomanufacturing capabilities and capacity to meet increasing customer demand for its services. This investment was made possible following the Company’s recent $32 million financing via a share placing on the London Stock Exchange.

Read more »

Abzena to pursue $5 million investment program in Bristol

Bristol PA, USA – Abzena intends to invest $5 million at its Bristol PA facility in order to increase its chemistry research and manufacturing services business for the biopharmaceutical industry. This investment was made possible following the Company’s recent $32 million financing via a share placing on the London Stock Exchange.

Read more »

AdAlta Quarterly Results and Cash Flow Statement

AdAlta Limited, an Australian based drug development company headquartered in Melbourne, announces its quarterly results.

Read more »

Clinigen and Onxeo initiate Managed Access programme for belinostat in Europe for patients with peripheral T-cell lymphoma (PTCL)

Clinigen Group plc’s (AIM: CLIN, ‘Clinigen’ or the ‘Group’) Idis Managed Access (‘MA’) division and Onxeo S.A (Euronext Paris, Nasdaq Copenhagen: ONXEO, ‘Onxeo’), have agreed to launch a Managed Access programme for belinostat (Beleodaq®) in Europe. Belinostat is for use in patients with relapsed or refractory peripheral T-cell lymphoma (‘PTCL’).

Read more »

Polyganics Announces Enrollment of the First Patient in its PROTECT NEURO Study

Groningen, The Netherlands - Polyganics, a privately held medical technology company focused on the commercialization of proprietary products and technologies for peripheral nerve reconstruction and regeneration, announced today that it has enrolled the first patient in its international PROTECT NEURO study to treat and prevent symptomatic neuroma. The first patient was treated at Stanford Medicine by Catherine Curtin, MD, associate professor of surgery.

Read more »

Recce calls for Australian investment in R&D to develop new antibiotics on the back of initiatives

SYDNEY Australia: Recce Limited (ASX: RCE), a pre-clinical-stage pharmaceutical company engaged in the development of a new class of synthetic antibiotics to treat serious infections, today welcomed calls by the Australasian Society for Infectious Diseases and the Australian Medical Association for Australia to do more to address the growing problem of bacterial resistance to antibiotics.

Read more »

Reinhard Kandera Appointed Chief Financial Officer of Hookipa Biotech

Vienna, Austria - Hookipa Biotech AG, a company pioneering a new class of immunotherapies for oncology and infectious diseases, today announces that Reinhard Kandera has joined the Company as Chief Financial Officer (CFO). Effective June 1st, 2017, he will also become a member of Hookipa’s management board.

Read more »

Agendia Appoints Patrick J. Balthrop Sr., Former CEO of Luminex, as Chairman

IRVINE, CA and AMSTERDAM – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, today announces the appointment of Patrick J. Balthrop Sr., former CEO of Luminex, as Non-Executive Chairman.

Read more »

Adherium to present at Respiratory Drug Delivery Europe 2017

Melbourne, Australia - Adherium Limited (ASX: ADR, ‘Adherium’), a global leader in digital health technologies addressing sub-optimal medication use in chronic disease, will be presenting at the Respiratory Drug Delivery Europe conference 2017 (RDD Europe), being held at the Palais des Congres d'Antibes in Nice, France, from 25-28 April 2017.

Read more »

Mission Therapeutics and University of Oxford Awarded Research Grant from the Michael J. Fox Foundation

CAMBRIDGE, UK – 11 April 2017 – On World Parkinson’s day, Mission Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat neurodegenerative diseases, cancer and other diseases with high unmet medical need, announced that it has been awarded a grant from the Michael J. Fox Foundation for Parkinson’s Research (MJFF).

Read more »

Recce Ltd - Operational Update

SYDNEY, Australia – Recce Limited (ASX: RCE), a pre-clinical-stage pharmaceutical company engaged in the development of a new class of synthetic antibiotics, provides an update on the significant pre-clinical and operational achievements over the past few months.

Read more »

AdAlta - Research Report

MELBOURNE Australia: AdAlta Limited (ASX: 1AD) advises Patersons Securities has published updated research coverage on the Company. A copy of the 13 page research report and other recent analyst reports are available on the Company’s website: http://adalta.com.au/investors/analyst-reports/

Read more »

Asceneuron Receives Regulatory Approval for Phase I Healthy Volunteer Study of Oral Tau Inhibitor

First-in-human trial of novel inhibitor targeting accumulation of toxic neurofibrillary tau tangles to fight neurodegenerative diseases including dementia

Lausanne, Switzerland - Asceneuron SA, an emerging leader in the development of innovative small molecules for neurodegenerative diseases, announced today the regulatory approval of its clinical trial application to initiate a first clinical study of ASN120290 (formerly known as ASN-561), belonging to a chemically novel group of O-GlcNAcase enzyme inhibitors. Based on preclinical studies, ASN120290 has the potential to become a new treatment for dementia.

Read more »

e-Therapeutics plc Appointment of Chief Executive Officer

Oxford, UK – e-Therapeutics plc (AIM: ETX), the drug discovery company, announces that further to the Company’s announcement on 9 January 2017, Dr. Raymond Barlow has today assumed his position as Chief Executive Officer.

Read more »

Abzena plc: Result of bookbuild

Cambridge, UK – Abzena plc (“Abzena” or the “Company”) is pleased to announce the result of the bookbuild announced earlier today (the “Placing”).

Read more »

SkinBioTherapeutics: First day of dealings

Manchester, UK - SkinBioTherapeutics plc (AIM: SBTX, the “Company”), a life science company focused on skin health, announces the commencement of dealings in its Ordinary Shares on AIM at 8:00a.m. today under the ticker code SBTX and the ISIN number: GB00BF33H870.

Read more »

Abzena plc: Proposed placing of £25 million

Cambridge, UK – Abzena plc (AIM: ABZA, “Abzena” or the “Group”), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, announces its intention to undertake a placing to raise approximately £25 million (the “Placing”) to expand further its service offering, capacity and capabilities.

Read more »

Crescendo Biologics Appoints Philip Bland-Ward as Chief Scientific Officer

Cambridge, UK – Crescendo Biologics Ltd (Crescendo), the developer of multi-functional Humabody® therapeutics, today announces that Dr Philip Bland-Ward has been appointed Chief Scientific Officer (CSO). The appointment will take effect in May 2017.

Read more »

Australia’s Bionic Vision Technologies Raises US$18 million (AU$23.5m) to Develop ‘Bionic Eye’ for Global Markets

MELBOURNE Australia: Retinal implant innovator Bionic Vision Technologies (BVT) today announced it had raised US$18 million (AU$23.5 million) from Hong Kong-based China Huarong International Holdings Ltd and State Path Capital Limited, to develop and commercialise its next generation devices aimed at restoring vision to the blind.

Read more »

Imanova Receives £1M Award from the MRC To Develop Early Markers of Dementia – the MIND-MAPS Study

London, UK - Following a £0.5m Medical Research Council (MRC) grant to implement new Positron Emission Tomography (PET) imaging tracers for mitochondrial dysfunction and synaptic loss, Imanova has been awarded an additional £1m of strategic funding from the MRC for clinical evaluation of this combination of tracers in Alzheimer’s disease and Parkinson’s disease - Stage 1 of the MIND-MAPS (Molecular Imaging of Neurodegenerative Disease – Mitochondria, Associated Proteins & Synapses) programme.

Read more »

Data from large animal study shows RECCE® 327 well tolerated

Recce Limited (ASX: RCE), a pre-clinical-stage pharmaceutical company engaged in the development of a new class of synthetic antibiotic, today released results from an independent study of its lead compound in large animals which showed the company’s lead asset RECCE® 327 was well tolerated with no adverse events.

Read more »

Clinigen hosts Unlicensed Medicines satellite symposium at 22nd Congress of EAHP

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or ‘the Group’), the global pharmaceuticals and services group, announces that its Idis GA division is holding a satellite symposium today on Access to Unlicensed Medicines as part of the 22nd Congress of European Association of Hospital Pharmacists (EAHP), taking place in Cannes, France.

Read more »

SkinBioTherapeutics intention to launch Initial Public Offering and list on AIM

Manchester, UK - SkinBioTherapeutics plc (“SkinBio” or the “Company”), a life science company focused on skin health, intends to seek Admission to AIM with an associated institutional and private client fundraising.

Read more »